Adzenys ER FDA Approval History
Last updated by Judith Stewart, BPharm on March 2, 2021.
FDA Approved: Yes (First approved September 15, 2017)
Brand name: Adzenys ER
Generic name: amphetamine
Dosage form: Extended-Release Liquid Suspension
Previous Name: NT-0201
Company: Neos Therapeutics, Inc.
Treatment for: ADHD
Adzenys ER (amphetamine) is an extended-release liquid suspension formulation of the central nervous system (CNS) stimulant amphetamine indicated for the treatment of ADHD in patients 6 years and older.
Development timeline for Adzenys ER
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
